Waubant E - Search Results

1

Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.

Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; ITN STAyCIS Study Group; ITN020AI Study Management Team. Waubant E, et al. Neurology. 2012 Apr 10;78(15):1171-8. doi: 10.1212/WNL.0b013e31824f7fdd. Epub 2012 Mar 28. Neurology. 2012. PMID: 22459680 Free PMC article. Clinical Trial.

2

A serial study of new MS lesions and the white matter from which they arise.

Goodkin DE, Rooney WD, Sloan R, Bacchetti P, Gee L, Vermathen M, Waubant E, Abundo M, Majumdar S, Nelson S, Weiner MW. Goodkin DE, et al. Among authors: waubant e. Neurology. 1998 Dec;51(6):1689-97. doi: 10.1212/wnl.51.6.1689. Neurology. 1998. PMID: 9855524

3

[Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].

Waubant E, Sloan R, Andersson PB, Goodkin D. Waubant E, et al. Rev Neurol (Paris). 1999;155 Suppl 2:S20-3. Rev Neurol (Paris). 1999. PMID: 10367321 Clinical Trial. French.

4

Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability.

Andersson PB, Waubant E, Gee L, Goodkin DE. Andersson PB, et al. Among authors: waubant e. Arch Neurol. 1999 Sep;56(9):1138-42. doi: 10.1001/archneur.56.9.1138. Arch Neurol. 1999. PMID: 10488816

5

A pilot study of MRI activity before and during interferon beta-1a therapy.

Waubant E, Goodkin DE, Sloan R, Andersson PB. Waubant E, et al. Neurology. 1999 Sep 11;53(4):874-6. doi: 10.1212/wnl.53.4.874. Neurology. 1999. PMID: 10489060

6

Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis.

Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G, Miller K. Waubant E, et al. Neurology. 1999 Oct 22;53(7):1397-401. doi: 10.1212/wnl.53.7.1397. Neurology. 1999. PMID: 10534241

7

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis.

Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson P, Stewart T, Nelson S, Fischbein N, Coyle PK, Frohman E, Jacobs L, Holcenberg J, Lee M, Mocci S. Goodkin DE, et al. Among authors: waubant e. Neurology. 2000 Apr 11;54(7):1414-20. doi: 10.1212/wnl.54.7.1414. Neurology. 2000. PMID: 10751249 Clinical Trial.

8

Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.

Kita M, Goodkin DE, Bacchetti P, Waubant E, Nelson SJ, Majumdar S. Kita M, et al. Among authors: waubant e. Neurology. 2000 May 9;54(9):1741-5. doi: 10.1212/wnl.54.9.1741. Neurology. 2000. PMID: 10802778

9

Interferon beta-1a in children with multiple sclerosis is well tolerated.

Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J, Miller C, Rensel M, Schwid S, Goodkin D. Waubant E, et al. Neuropediatrics. 2001 Aug;32(4):211-3. doi: 10.1055/s-2001-17370. Neuropediatrics. 2001. PMID: 11571702

10

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. Hauser SL, et al. Among authors: waubant e. N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383. N Engl J Med. 2008. PMID: 18272891 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

339 results

Search Page